The Latest in Financial & Business News

Scientist Nour Tabidi prepares a DNA sample in a lab at Thermo Fisher's recently opened manufacturing plant in Plainville. The plant specializes in gene therapies.

Thermo Fisher just opened a $180 million plant. Executives already are talking about expanding.

The two-story building in Plainville underscores the company’s commitment to the growing field of gene therapy, which has given hope to people with deadly inherited diseases.

Demand for life sciences lab space has slowed in Boston area and nationally, report says
Real estate giant JLL depicted an overbuilt market that is forcing building owners, who only recently commanded top dollar for premium lab space, to reduce rents and scramble for tenants.

Shares of biotech Neumora retreat after raising $250 million in IPO
Neumora's stock began trading early Friday afternoon with the ticker NMRA, and quickly fell 7.3 percent on a day of broad market declines.

Saudi fund sets up in Boston to plow $1 billion a year into research and drugs to extend life
The source of funding may present a dilemma for some scientists and entrepreneurs because of the kingdom’s record on human rights.

Vertex scientists share $3 million prize for developing the company’s cystic fibrosis drugs
Their work has dramatically extended the life expectancy of CF patients.

Generate Biomedicines raises $273 million in latest round of funding
The money arrives amid a slump in biotech investments this year, as investors stick to the sidelines because of economic uncertainty and interest rate hikes.

FROM OUR PARTNERS

product by Studio/B. What is this?This content was produced by Boston Globe Media's Studio/B in collaboration with the advertiser. The news and editorial departments of the Boston Globe had no role in its production or display.

product by BG BRANDLAB. What is this?This content was produced by Boston Globe Media's Studio/B in collaboration with the advertiser. The news and editorial departments of the Boston Globe had no role in its production or display.

More Life Sciences Headlines

(From left to right) Fred van Goor, Sabine Hadida, and Paul Negulescu, three scientists with Vertex Pharmaceuticals, will share a $3 million Breakthrough Prize for revolutionizing the treatment of cystic fibrosis. All three scientists work at the company’s cystic fibrosis research center in San Diego.

Vertex scientists share $3 million prize for developing the company’s cystic fibrosis drugs

Their work has dramatically extended the life expectancy of CF patients. 9:00 a.m.

The building in Somerville that houses Generate Biomedicine .

Generate Biomedicines raises $273 million in latest round of funding

The money arrives amid a slump in biotech investments this year, as investors stick to the sidelines because of economic uncertainty and interest rate hikes. 6:01 a.m.

A panel of expert advisers to the Food and Drug Administration on Wednesday concluded that the benefits of a drug from Alnylam Pharmaceuticals outweighed its risks in the treatment of a form of cardiomyopathy, a disease of the heart muscle.

FDA advisers are lukewarm about expanding use of Alnylam drug to heart patients

The experts agreed with FDA scientists that the benefits to patients in a clinical trial compared to a placebo were modest at best. 7:09 p.m.

RI BUSINESS

Similasan AG Pink Eye Relief and CVS Health Pink Eye Drops at a CVS store in downtown Boston on Sept. 12, 2023.

CVS, Walgreens illegally marketed ‘unapproved’ eye drops, FDA says

CVS and Walgreens claim to have stopped selling the eye drops, and consumers who previously purchased them can get full refunds. 2:27 p.m.

Moderna, based in Cambridge, is seeking to broaden its line of vaccines.

Moderna poised to seek flu shot approval after trial results

In a trial on over 2,400 adults, the reformulated shot produced a stronger immune response against all four strains of the influenza virus than a traditional flu vaccine, the company said in a statement Wednesday. 8:45 a.m.

Nick Leschly said he will step down as CEO of Cambridge biotech 2Seventy and become chairman of the board of directors.

Cambridge biotech 2Seventy Bio slashes 40 percent of workforce

The job cuts are the latest in a series of layoffs in the biopharmaceutical industry. 8:42 a.m.

Henry Gosebruch, a former executive for drug giant AbbVie, is now president and chief executive officer of Neumora Therapeutics.

Neumora seeks to become the second Massachusetts biotech to go public in 2023

Neumora hopes to raise up to $265 million from investors, leaving it with a market value of as much as $2.7 billion. 5:57 p.m.

On Monday, the FDA approved BioLineRx's new drug, Aphexda, which helps doctors collect stem cells to treat patients with multiple myeloma.

FDA clears drug to help harvest stem cells to treat multiple myeloma patients

The injectable will be sold by an Israeli biotech BioLineRx, which has its US headquarters in Waltham. 2:06 p.m.